Preliminay study of urinary syndecan- 1 measurement to investigate association with onset of vascular- endothelial injury in patients with sepsis

A preliminary study to investigate the efficacy of urinary syndecan-1 as a marker of glycocalyx collapsing and subsequential vascular endothelial infringement in patients with sepsis - PIE US-1M VIPS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030230068

Enrollment

Registered

2023-05-14

Start date

2023-02-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis sepsis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Sepsis and septic shock patients who need crinical care at general intensive care unit ( GICU) in our institution. Define of sepsis: Infection diagnoted or suspected, with organ dysfunction with acute elevation of SOFA score over two points. Define of septic shock: Sepsis with high blood lactate acid above 2 mmol/L (18 mg/dL), and need vasocontractive drug in addition to fluid resuscitation to keep mean arterial blood bressure over 65 mmHg.

Exclusion criteria

Exclusion criteria: Patients who are not gotten concented, not available to insert cathetel into bladder, not available to take urea, emergent and obvious critical life- threatning situation, and have any possiblity to effect this study.

Design outcomes

Primary

Measure	Time frame
Comparison of both blood and urinary syndecan -1 at 4 time points below start of staying GICU, 1 day after start of treatment, 2 day after start of treatment, end of staying GICU	—

Secondary

Measure	Time frame
Compare trend of both blood and urinary syndecan- 1, 30 days mortality etc in two groups which allocated to severe group and non- severe group with SOFA score of entering into GICU.	—

Contacts

Public ContactTazawa Kazumasa

Saitama Medical Center, Saitama Medical University

wacchi7@gmail.com+81-492283654

Outcome results